TPP and the Dire Threat to Affordable Drug Prices

Drug prices in the U. S. are already approaching a crisis point for many patients unable to afford their prices, often despite being insured. These examples indicate how serious this problem has become:

 The use of prescription drugs by Americans, partly driven by direct-to-consumer advertising since the 1990s, has reached an all-time high.

Continue reading

Posted in Evergreening, TPP, Uncategorized | Leave a comment

Gilead using Data Exclusivity in Ukraine to monopolise Hep-C drug Sofosbuvir

Impact of data exclusivity in Ukraine on access to affordable generic version of sofosbuvir ( direct acting antiviral – DAA used for Hepatitis C treatment)

 Chronology of events/facts

  • Pharmasset originally developed Sofosbuvir. Gilead Sciences acquired Pharmasset including its Hepatititis C compounds sofosbuvir for $11.2 billion in 2012.
  • December 2013 USFDA approves sofosbuvir for inclusion in Hepatitis C treatment regimens, dramatically improving cure rates for the disease.  Continue reading
Posted in Data Exclusivity, Patent, Patent Opposition, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

The Downfall Of Invention: A Broken Patent System

By Tahir Amin, The Huffington Post | August 17, 2016

The cost of dozens of brand-name drugs have nearly doubled in just the past five years. Public outrage over drug prices extends from Capitol Hill to the presidential candidates to patients. In response, pharmaceutical executives are spending more on lobbying and marketing. Yet for all this attention, most of the proposed solutions for reducing prescription drug costs—tougher negotiations, appeals for transparent R&D costs or investigations into insurers—miss one of the primary sources of the problem: the way we award patents. Continue reading

Posted in Innovation, Patent, TRIPS, Uncategorized | Leave a comment

The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia

Authors: Joel Lexchin & Deborah Gleeson| Publication: Sage Journals

Int J Health Serv August 11, 20160020731416662612

Abstract

The Trans Pacific Partnership Agreement (TPP) is a large regional trade agreement involving 12 countries. It was signed in principle in February 2016 but has not yet been ratified in any of the participating countries. The TPP provisions place a range of constraints on how governments regulate the pharmaceutical sector and set prices for medicines. This article presents a prospective policy analysis of the possible effects of the TPP on these two points in Canada and Australia. Continue reading

Posted in TPP, Uncategorized | Leave a comment

India Seeks Protection With New Model Bilateral Investment Treaty

By Prabhas Ranjan, The Wire| February 2, 2016

Pricked after being sued by foreign investors under different bilateral investment treaties (BIT), India has adopted a new model. But it could impact the ongoing India-US BIT negotiations.

India has adopted a new model BIT.

Provoked by foreign investors suing India under different bilateral investment treaties (BITs), the government recently adopted a new model BIT. Countries develop a model BIT to use as a template to negotiate investment treaties, but on its own, a model BIT has very limited legal value. The 2015 model BIT replaces the 2003 model, which was fairly investor-friendly. Most of India’s existing BITs, signed with more than 70 countries, are based on the 2003 model. The adoption of the new model BIT heralds a new era in India’s engagement with foreign investment and investment treaty practice. Continue reading

Posted in BITS, Compulsory Licensing, TRIPS, Uncategorized, WTO | Leave a comment

Call to remove IP clauses from trade pact

Source: The Hindu | August 16, 2016

Regional Comprehensive Economic Partnership (RCEP) deal could hit supply of cheap Indian drugs

As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam on Monday, humanitarian aid organisation Médecins Sans Frontières (MSF) has called for the removal of intellectual property provisions — known as the TRIPS-plus provisions — from the agreement. The talks are scheduled for August 15-19. Continue reading

Posted in Data Exclusivity, IPR, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

India’s new stance at RCEP may benefit China

India may offer tariff reduction in a much higher number of commodities to China with whom it has a staggering $52.7 billion trade deficit

By Asit Ranjan Mishra, Live Mint | August 9, 2016

New Delhi: In a major shift in stance that may benefit China, India has agreed to provide similar tariff cuts to all Regional Comprehensive Economic Partnership agreement (RCEP) member countries with limited deviation. Continue reading

Posted in Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment